Greenland Mines Ltd. (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year.
This patent issuance is a significant milestone for Greenland Mines as it strengthens the company’s position in the rapidly evolving gene therapy landscape. The Klotho gene has been associated with longevity and cognitive function, and its therapeutic potential in neurodegenerative diseases has garnered increasing scientific interest. By securing patent protection in Canada, a key market for pharmaceutical innovation, Greenland Mines is positioning itself to potentially commercialize treatments for conditions that currently have limited therapeutic options.
The company’s biotech division is one of two operating segments, alongside its mining division focused on rare earth and precious metals projects in Greenland. This dual strategy aims to build a multi-asset platform with exposure to both critical minerals and advanced therapeutics. The patent news underscores the company’s commitment to advancing its Klotho-based programs, with KLTO-202 for ALS moving into GMP manufacturing and regulatory discussions expected later this year.
For investors, the patent adds a layer of protection to the company’s intellectual property, potentially enhancing its valuation and partnership opportunities. The broader implications for patients are substantial, as successful development of these therapies could address significant unmet medical needs in neurodegenerative diseases. However, the company still faces considerable clinical and regulatory hurdles before any products reach the market.
To view the full press release, visit https://ibn.fm/x2pHA. More information about Greenland Mines is available at its newsroom at https://ibn.fm/GRML.
